These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33453330)

  • 1. MAFLD: A holistic view to redefining fatty liver disease.
    Eslam M; George J
    J Hepatol; 2021 Apr; 74(4):983-985. PubMed ID: 33453330
    [No Abstract]   [Full Text] [Related]  

  • 2. From NAFLD to MAFLD: a "redefining" moment for fatty liver disease.
    Zheng KI; Fan JG; Shi JP; Wong VW; Eslam M; George J; Zheng MH
    Chin Med J (Engl); 2020 Oct; 133(19):2271-2273. PubMed ID: 32701591
    [No Abstract]   [Full Text] [Related]  

  • 3. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2020; 14(4):695-696. PubMed ID: 32442920
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to: Comparison of MAFLD and NAFLD diagnostic criteria in real world.
    Nguyen VH; Le MH; Henry L; Cheung R
    Liver Int; 2020 Dec; 40(12):3145. PubMed ID: 32941668
    [No Abstract]   [Full Text] [Related]  

  • 5. Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data.
    Targher G
    Liver Int; 2020 Nov; 40(11):2879-2880. PubMed ID: 32738082
    [No Abstract]   [Full Text] [Related]  

  • 6. Authors' response to 'Concordance of MAFLD and NAFLD diagnostic criteria in "real-world" data'.
    Huang J; Kumar R; Zhu Y; Lin S
    Liver Int; 2020 Nov; 40(11):2880-2881. PubMed ID: 32889767
    [No Abstract]   [Full Text] [Related]  

  • 7. MAFLD: A game changer redefining fatty liver disease for adults and children.
    Eslam M; George J
    J Hepatol; 2021 Apr; 74(4):992-994. PubMed ID: 33453327
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation.
    Carnagarin R; Tan K; Adams L; Matthews VB; Kiuchi MG; Marisol Lugo Gavidia L; Lambert GW; Lambert EA; Herat LY; Schlaich MP
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
    Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
    Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAFLD, patient-centred care, and APASL.
    Sarin SK; Eslam M; Fan JG; Lin HC; George J; Omata M
    Hepatol Int; 2022 Oct; 16(5):1032-1034. PubMed ID: 36070122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
    Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
    BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
    Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
    Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study.
    Niriella MA; Ediriweera DS; Kasturiratne A; De Silva ST; Dassanayaka AS; De Silva AP; Kato N; Pathmeswaran A; Wickramasinghe AR; de Silva HJ
    PLoS One; 2021; 16(2):e0245762. PubMed ID: 33534815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAFLD, MAFLD and DAFLD.
    Mantovani A; Dalbeni A
    Dig Liver Dis; 2020 Dec; 52(12):1519-1520. PubMed ID: 33012657
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease.
    Oh JH; Lee JH; Cho MS; Kim H; Chun J; Lee JH; Yoon Y; Kang W
    Nutrients; 2021 Mar; 13(3):. PubMed ID: 33801023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Insulin Resistance in MAFLD.
    Sakurai Y; Kubota N; Yamauchi T; Kadowaki T
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy.
    Xian YX; Weng JP; Xu F
    Chin Med J (Engl); 2020 Dec; 134(1):8-19. PubMed ID: 33323806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redefining fatty liver disease: an international patient perspective.
    Shiha G; Korenjak M; Eskridge W; Casanovas T; Velez-Moller P; Högström S; Richardson B; Munoz C; Sigurðardóttir S; Coulibaly A; Milan M; Bautista F; Leung NWY; Mooney V; Obekpa S; Bech E; Polavarapu N; Hamed AE; Radiani T; Purwanto E; Bright B; Ali M; Dovia CK; McColaugh L; Koulla Y; Dufour JF; Soliman R; Eslam M
    Lancet Gastroenterol Hepatol; 2021 Jan; 6(1):73-79. PubMed ID: 33031758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.
    Vasques-Monteiro IML; Souza-Mello V
    World J Gastroenterol; 2021 Apr; 27(16):1738-1750. PubMed ID: 33967554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAFLD criteria overlooks a number of patients with severe steatosis: Is it clinically relevant?
    Huang J; Kumar R; Wang M; Zhu Y; Lin S
    J Hepatol; 2020 Nov; 73(5):1265-1267. PubMed ID: 32819754
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.